Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 974
1.
Am J Trop Med Hyg ; 110(3): 487-490, 2024 Mar 06.
Article En | MEDLINE | ID: mdl-38350151

Type 2 leprosy reaction is a type of acute inflammation that predominantly affects borderline lepromatous leprosy and lepromatous leprosy patients and occurs before, during, or after therapy. The atypical variant, which resembles Sweet syndrome, could easily lead to misdiagnosis. Here, we report a case of a 52-year-old man who presented with type 2 leprosy reaction that mimicked Sweet syndrome. In addition, we review published cases and summarize their features to raise awareness of this atypical variant to enable improved diagnosis and management.


Hypersensitivity , Leprosy, Borderline , Leprosy, Lepromatous , Sweet Syndrome , Male , Humans , Middle Aged , Sweet Syndrome/diagnosis , Sweet Syndrome/drug therapy , Leprosy, Lepromatous/diagnosis , Leprosy, Lepromatous/drug therapy
2.
Am J Trop Med Hyg ; 110(3): 483-486, 2024 Mar 06.
Article En | MEDLINE | ID: mdl-38266303

Leprosy is a global health issue, causing long-term functional morbidity and stigma. Rapid diagnosis and appropriate treatment are important; however, early diagnosis is often challenging, especially in nonendemic areas. Here, we report a case of borderline lepromatous leprosy accompanied by dapsone-induced (neutropenia, anemia, and methemoglobinemia) and clofazimine-induced (skin discoloration and ichthyosis) side effects and type 1 leprosy reactions during administration of the multidrug therapy. The patient completely recovered without developing any deformities or visual impairment. To ensure early diagnosis and a favorable outcome, clinicians should be aware of the diminished sensation of skin lesions as a key physical finding and manage the drug toxicities and leprosy reactions appropriately in patients on multidrug therapy.


Hypersensitivity , Leprosy, Borderline , Leprosy, Lepromatous , Leprosy, Multibacillary , Leprosy , Peripheral Nervous System Diseases , Skin Diseases, Bacterial , Humans , Clofazimine/adverse effects , Dapsone/adverse effects , Drug Therapy, Combination , Leprostatic Agents/adverse effects , Leprosy/pathology , Leprosy, Borderline/diagnosis , Leprosy, Borderline/drug therapy , Peripheral Nervous System Diseases/drug therapy , Leprosy, Multibacillary/drug therapy , Leprosy, Lepromatous/diagnosis , Leprosy, Lepromatous/drug therapy , Leprosy, Lepromatous/pathology
3.
Am J Dermatopathol ; 45(12): 843-846, 2023 Dec 01.
Article En | MEDLINE | ID: mdl-37883932

ABSTRACT: Leprosy is a disease caused by Mycobacterium leprae that, depending on a patient's baseline susceptibility and immune system function, can present in a wide variety of ways. The host's immune system response to the infection can be cell-mediated or humoral and can be further altered by changes in immune function or treatment. Depending on the time at which a skin biopsy is taken from affected areas, different inflammatory cell types are present, and the histopathology can mimic that of other infectious, autoimmune, or malignant entities, especially when the clinical information provided is vague. We present a case of a 24-year-old Micronesian woman who initially presented immediately postpartum with clinical and histopathological findings suggestive of urticarial vasculitis, but a subsequent biopsy resulted in a diagnosis of erythema nodosum leprosum reaction and borderline multibacillary leprosy. This case illustrates an unusual clinical and histological presentation of M. leprae and highlights the importance of clinical history.


Leprosy, Borderline , Leprosy , Urticaria , Vasculitis , Female , Humans , Young Adult , Adult , Mycobacterium leprae , Leprosy, Borderline/diagnosis , Leprosy, Borderline/drug therapy
4.
Turk J Pediatr ; 65(5): 862-867, 2023.
Article En | MEDLINE | ID: mdl-37853977

BACKGROUND: Leprosy in children is a strong indicator of the recent failure of leprosy control and disease transmission programs. For twenty-two years, leprosy has been declared `eliminated as a public health hazard,` yet new cases continue to emerge in endemic areas. The new case detection rate among the child population was recorded at 4.4 per million children. Because of their underdeveloped or neonatal immunity and exposure to intrafamilial contacts, children tend to be the most vulnerable population. CASE: We present a case of the borderline lepromatous type of leprosy in a 9-year-old Indonesian male patient with the chief complaint of three stiff fingers on his left hand that began four years ago and hypopigmented patches on the back and buttocks that began five years ago. In this case, there was a history of leprosy in his mother`s sister, who had died. Leprosy in the patient was suspected of possibly being transmitted from his mother`s sister who had intense contact with the patient. The results of bacteriological examination with Ziehl- Neelsen staining of tissue scrapings found acid-fast bacilli. He was treated with a multibacillary multidrug regimen for 12 months. Periodical observations after the patient received the treatment revealed no new spots on the patient`s skin, some of the previous hypopigmented patches seemed to fade, especially those on the back. CONCLUSIONS: In the absence of an effective vaccine, early diagnosis and treatment are critical in preventing disability and deformity and reducing the physical, psychosocial, and economic burden of the disease.


Leprosy, Borderline , Leprosy, Lepromatous , Leprosy, Multibacillary , Leprosy , Infant, Newborn , Child , Humans , Male , Leprosy, Lepromatous/diagnosis , Leprosy, Lepromatous/drug therapy , Leprosy, Borderline/diagnosis , Leprosy, Borderline/drug therapy , Leprosy/diagnosis , Skin
5.
Am J Trop Med Hyg ; 109(2): 345-349, 2023 08 02.
Article En | MEDLINE | ID: mdl-37339763

In leprosy, early diagnosis is crucial to prevent transmission and onset of disabilities of the disease. The purpose of this study was to determine usefulness of quantitative real-time polymerase chain reaction (PCR) in clinically diagnosed cases of leprosy. Thirty-two leprosy cases were included. The real-time PCR was performed using commercial kit targeting Mycobacterium leprae-specific insertion sequence element. The slit skin smear was positive in two (22.2%) borderline tuberculoid (BT) patients, five (83.3%) borderline lepromatous (BL) patients, and seven (50%) lepromatous leprosy (LL). The positivity of quantitative real-time PCR in BT, BL, LL, and pure neuritic leprosy were 77.8%, 83.3%, 100%, and 33.3%, respectively. Using histopathology as the gold standard, sensitivity of quantitative real-time PCR was 93.1%, and specificity was 100%. The DNA load was higher in LL (3,854.29/106 cells), followed by BL (140.37/106 cells), and BT (2.69/106 cells). Because of the high sensitivity and specificity of real-time PCR, our study strongly suggests the use of real-time PCR as a diagnostic tool for leprosy.


Leprosy, Borderline , Leprosy, Lepromatous , Leprosy, Paucibacillary , Leprosy , Humans , Mycobacterium leprae/genetics , Real-Time Polymerase Chain Reaction , Leprosy/pathology , Leprosy, Lepromatous/diagnosis , Leprosy, Paucibacillary/diagnosis
7.
Goiânia; SES-GO; 20 jan. 2023. 1-10 p. graf, tab.(Boletim epidemiológico: frequência de contatos não examinados de casos novos de hanseníase virchowiana e dimorfa com baciloscopia positiva - Goiás, 24, 1).
Monography Pt | LILACS, CONASS, ColecionaSUS, SES-GO | ID: biblio-1412667

A hanseníase é uma doença infecciosa crônica, causada pelo Mycobacterium leprae, um bacilo com tropismo pela pele e pelos nervos periféricos, com potencial de provocar deformidades físicas e incapacidades. O período de incubação da doença é longo, de 2 a 7 anos, podendo chegar a 20 anos ou mais. Este estudo consiste em uma análise retrospectiva, quantitativa, descritiva, das fichas de notificação do Sistema de Informação de Agravos de Notificação - SINAN dos pacientes com diagnóstico de hanseníase (CID A30), nos anos de 2017 a 2021 e os Boletins de acompanhamento das referidas fichas


Leprosy is a chronic infectious disease caused by Mycobacterium leprae, a bacillus with tropism for the skin and peripheral nerves, with the potential to cause physical deformities and disabilities. The incubation period of the disease is long, from 2 to 7 years, and can reach 20 years or more. This study consists of a retrospective, quantitative, descriptive analysis of the notification of the Notifiable Diseases Information System - SINAN of patients diagnosed with leprosy (ICD A30), in the years 2017 to 2021 and the follow-up Bulletins of the referred forms


Humans , Leprosy, Lepromatous/transmission , Leprosy, Borderline , Leprosy, Lepromatous/diagnosis , Leprosy, Lepromatous/prevention & control , Leprosy, Lepromatous/epidemiology , Leprosy, Multibacillary , Leprosy, Paucibacillary , Leprosy
8.
Int J Mycobacteriol ; 11(4): 457-459, 2022.
Article En | MEDLINE | ID: mdl-36510935

Leprosy and human immunodeficiency virus (HIV) often mimic clinical features of connective tissue disease (CTD). They can present such as lupus, rheumatoid arthritis, scleroderma, or overlap syndromes and it sometimes creates confusion about the diagnosis. Serology may not be enough to differentiate the two and effective tissue biopsies are often the answer. We report the case of a 38-year-old female, who presented clinically with features of multisystem involvement suspected to be CTD, but was found to have dual infection: HIV and borderline tuberculoid leprosy.


HIV Infections , Leprosy, Borderline , Leprosy , Female , Humans , Adult , HIV , Leprosy/complications , Leprosy/diagnosis , Biopsy , HIV Infections/complications , HIV Infections/diagnosis
9.
BMJ Case Rep ; 15(10)2022 Oct 03.
Article En | MEDLINE | ID: mdl-36192029

Leprosy was eliminated globally in 2000, but it continues to be endemic in developing countries like India, Brazil and Indonesia, with a prevalence of 0.57/10 000 persons in India (2020). At the end of the year 2020, the prevalence was 129 389, and oral manifestation of the leprosy is luncommon. We hereby report a case of a female patient in her late 30s who presented with palatal perforation. Following a thorough history taking and full body clinical examination, we arrived at a diagnosis of leprosy, and prompt treatment was initiated. Knowledge of cases like this becomes important as the oral lesion is said to form an essential source of leprosy dissemination in the community, and awareness about them becomes crucial, demanding immediate attention.


Leprosy, Borderline , Leprosy, Lepromatous , Leprosy, Multibacillary , Leprosy , Female , Humans , India/epidemiology , Leprosy/diagnosis , Leprosy, Borderline/epidemiology , Leprosy, Borderline/pathology , Leprosy, Lepromatous/complications , Leprosy, Lepromatous/diagnosis , Leprosy, Lepromatous/drug therapy , Prevalence
10.
PLoS Negl Trop Dis ; 16(10): e0010799, 2022 10.
Article En | MEDLINE | ID: mdl-36264976

BACKGROUND: Leprosy is rare in the United Kingdom (UK), but migration from endemic countries results in new cases being diagnosed each year. We documented the clinical presentation of leprosy in a non-endemic setting. METHODS: Demographic and clinical data on all new cases of leprosy managed in the Leprosy Clinic at the Hospital for Tropical Diseases, London between 1995 and 2018 were analysed. RESULTS: 157 individuals with a median age of 34 (range 13-85) years were included. 67.5% were male. Patients came from 34 different countries and most contracted leprosy before migrating to the UK. Eighty-two (51.6%) acquired the infection in India, Sri Lanka, Bangladesh, Nepal and Pakistan. 30 patients (19.1%) acquired leprosy in Africa, including 11 from Nigeria. Seven patients were born in Europe; three acquired their leprosy infection in Africa, three in South East Asia, and one in Europe. The mean interval between arrival in the UK and symptom onset was 5.87 years (SD 10.33), the longest time to diagnosis was 20 years. Borderline tuberculoid leprosy (n = 71, 42.0%), and lepromatous leprosy (n =, 53 33.1%) were the commonest Ridley Jopling types. Dermatologists were the specialists diagnosing leprosy most often. Individuals were treated with World Health Organization recommended drug regimens (rifampicin, dapsone and clofazimine). CONCLUSION: Leprosy is not a disease of travellers but develops after residence in an leprosy endemic area. The number of individuals from a leprosy endemic country reflect both the leprosy prevalence and the migration rates to the United Kingdom. There are challenges in diagnosing leprosy in non-endemic areas and clinicians need to recognise the symptoms and signs of leprosy.


Leprosy, Borderline , Leprosy, Lepromatous , Leprosy , Humans , Male , Adolescent , Young Adult , Adult , Middle Aged , Aged , Aged, 80 and over , Female , London , Leprosy/epidemiology , Leprosy, Lepromatous/drug therapy , Leprosy, Borderline/drug therapy , Nigeria
12.
An Bras Dermatol ; 97(2): 231-235, 2022.
Article En | MEDLINE | ID: mdl-34996656

Patients with lepromatous or borderline leprosy may present two types of vasculonecrotic reactions: Lucio's phenomenon (LP) and necrotic erythema nodosum leprosum (nENL). These are serious conditions, which mostly lead to life-threatening infectious and thrombotic complications. The authors report the case of a patient with leprosy recurrence associated with an atypical type II reaction with LP characteristics on histopathology.


Erythema Nodosum , Leprosy, Borderline , Leprosy, Lepromatous , Leprosy, Multibacillary , Leprosy , Erythema Nodosum/pathology , Humans , Leprosy/complications , Leprosy, Lepromatous/complications , Leprosy, Lepromatous/pathology , Leprosy, Multibacillary/complications , Necrosis
13.
Trop Doct ; 52(2): 354-356, 2022 Apr.
Article En | MEDLINE | ID: mdl-35006027

Reactions in leprosy represent sudden shift in the immunological response and are seen in 11-25% of affected patients. It can be seen before, during or after the completion of multidrug therapy (MDT).1 Two types of reactions are recognized; Type 1 reaction (T1R), seen in borderline leprosy, affecting mainly skin and nerves; type 2 reaction (T2R) or erythema nodosum leprosum (ENL), seen in lepromatous leprosy, characterized by systemic features in addition to cutaneous lesions. Trophic ulcers and ulcerating ENL are well known entities while cutaneous ulceration in T1R is extremely rare; we describe an immune-competent woman with cutaneous ulceration as a presenting feature to highlight the need to recognize this entity at the earliest opportunity.


Erythema Nodosum , Leprosy, Borderline , Leprosy, Lepromatous , Skin Ulcer , Drug Therapy, Combination , Erythema Nodosum/diagnosis , Erythema Nodosum/drug therapy , Erythema Nodosum/etiology , Female , Humans , Leprostatic Agents/therapeutic use , Leprosy, Borderline/complications , Leprosy, Borderline/drug therapy , Leprosy, Borderline/pathology , Leprosy, Lepromatous/complications , Leprosy, Lepromatous/diagnosis , Leprosy, Lepromatous/drug therapy , Skin Ulcer/diagnosis , Skin Ulcer/drug therapy , Skin Ulcer/etiology
17.
An. bras. dermatol ; 96(1): 97-99, Jan.-Feb. 2021. graf
Article En | LILACS | ID: biblio-1152798

Abstract Leprosy is a chronic infectious disease caused by Mycobacterium leprae and, depending on the host immune status, presents different clinical forms. This report describes the case of a 46-year-old man who had hypoesthetic lesions in the infrahyoid region for 30 days. The bacilloscopy was negative. The anatomopathological examination showed alterations corresponding to the tuberculoid pole (epithelioid histiocytes) and virchowian pole (foamy histiocytes), compatible with borderline-virchowian leprosy (Ridley and Jopling classification). Rapid tests for HIV I, II, and syphilis were positive, with a CD4 count of 223. The patient started treatment with multibacillary multidrug therapy, antiretroviral therapy, and benzathine penicillin, with marked clinical improvement in two months.


Humans , Male , Leprosy, Borderline/drug therapy , Leprosy/drug therapy , Drug Therapy, Combination , Leprostatic Agents/therapeutic use , Middle Aged , Mycobacterium leprae
19.
An Bras Dermatol ; 96(1): 97-99, 2021.
Article En | MEDLINE | ID: mdl-33288364

Leprosy is a chronic infectious disease caused by Mycobacterium leprae and, depending on the host immune status, presents different clinical forms. This report describes the case of a 46-year-old man who had hypoesthetic lesions in the infrahyoid region for 30 days. The bacilloscopy was negative. The anatomopathological examination showed alterations corresponding to the tuberculoid pole (epithelioid histiocytes) and virchowian pole (foamy histiocytes), compatible with borderline-virchowian leprosy (Ridley and Jopling classification). Rapid tests for HIV I, II, and syphilis were positive, with a CD4 count of 223. The patient started treatment with multibacillary multidrug therapy, antiretroviral therapy, and benzathine penicillin, with marked clinical improvement in two months.


Leprosy, Borderline , Leprosy , Drug Therapy, Combination , Humans , Leprostatic Agents/therapeutic use , Leprosy/drug therapy , Leprosy, Borderline/drug therapy , Male , Middle Aged , Mycobacterium leprae
20.
In. Soares, Cleverson Teixeira. Histopathological diagnosis of leprosy. Sharjah, Bentham Science Publishers;Bentham Books, 2021. p.73-111, ilus, tab.
Monography En | SES-SP, HANSEN, HANSENIASE, SESSP-ILSLPROD, SES-SP, SESSP-ILSLACERVO, SES-SP | ID: biblio-1292077

Leprosy is a long-term spectrum disease and can present various clinical and histopathological aspects. Between the two poles of leprosy, there is a wide range of types, consisting of intermediate or borderline forms. In this chapter, the clinical, histopathological, and bacilloscopic characteristics of the intermediate forms (borderlibe-tuberculoid [BT], borderline-borderline [BB], and borderline lepromatous [BL]) are presented and discussed. The main clinical and pathological characteristics that allow the diagnosis and classification of leprosy among the different borderline forms are described and illustrated in panel form, as well as their most significant clinical and histopathological differential diagnoses are also discussed. The clinical-pathological classification of this disease has important implications in the choice of the correct treatment, the understanding of the pathophysiology, and the development of the reaction phenomena typical of leprosy,.


Leprosy, Borderline/pathology , Leprosy, Paucibacillary/pathology , Leprosy, Borderline/diagnosis , Leprosy, Paucibacillary/diagnosis
...